Emily C Lin

US Patent:

20120282599, Nov 8, 2012

Filed:

Apr 26, 2012

Appl. No.:

13/456738

Inventors:

Jiong Wu - Los Gatos CA, US
Marilou Coleman - Newark CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US
Emily H. Lin - Cupertino CA, US

International Classification:

C12M 1/42
G01N 21/64

US Classification:

435 61, 4352872

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

US Patent:

6524798, Feb 25, 2003

Filed:

Jun 12, 2000

Appl. No.:

09/592120

Inventors:

Simon Goldbard - San Jose CA
Tsai-Hsia Hong - San Mateo CA
Michael A. Zoccoli - Moraga CA
Emily Lin - San Jose CA

Assignee:

Applied Imaging Corporation - Santa Clara CA

International Classification:

G01N 3353

US Classification:

435 6, 435 71, 435 75, 435 79, 536 2431, 536 2532

Abstract:

The invention provides a high efficiency method for combined immunocytochemistry and in situ hybridization. In one aspect, the method is used to simultaneously determining a cell phenotype and genotype by contacting a cell with an antigen-specific antibody bound to a ligand, contacting the cell with polynucleotide probe to form a complex of the probe and a nucleic acid in the cell, contacting the cell with a detectably labeled anti-ligand, and detecting the polynucleotide-probe complex and the anti-ligand-ligand complex. The presence of the anti-ligand is correlated with the presence of the antigen and the presence of the probe-nucleic acid complex is correlated with the presence of the nucleic acid in the cell.

US Patent:

20210130866, May 6, 2021

Filed:

Aug 25, 2020

Appl. No.:

17/002089

Inventors:

- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jihping Yang - Palo Alto CA, US

International Classification:

C12Q 1/04
G01N 33/50

Abstract:

Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

US Patent:

20200141858, May 7, 2020

Filed:

Oct 15, 2019

Appl. No.:

16/653489

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 33/80
G01N 21/64
G01N 33/49

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

US Patent:

20190204301, Jul 4, 2019

Filed:

Sep 7, 2017

Appl. No.:

16/330289

Inventors:

- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jiong Wu - Los Gatos CA, US

International Classification:

G01N 33/50
G01N 33/52

Abstract:

Methods, devices, and systems for automated cellular analysis of a body fluid sample are disclosed. The methods, devices, and systems apply watershed transform to data, generated by flowing a body fluid sample through a flow cytometer, to determine threshold(s) to be used for analysis of the data.

US Patent:

20180334699, Nov 22, 2018

Filed:

May 14, 2018

Appl. No.:

15/979230

Inventors:

- Abbott Park IL, US
Emily H. Lin - Cupertino CA, US
Jihping Yang - Palo Alto CA, US

International Classification:

C12Q 1/04
G01N 33/50

Abstract:

Herein is provided a simple, reliable and accurate method for cellular analysis on hematology analyzers. In various aspects, the methods provide separation and/or differentiation between red blood cells (RBCs) and white blood cells (WBCs) by utilizing a fluorescent dye to selectively stain WBCs such that they emit stronger fluorescence signals. The method provides optimal detection limits on WBCs and RBCs, thereby allowing analysis of samples with sparse cellular concentrations. As few as one reagent may be used to prepare a single dilution for body fluid analysis, in order to simplify the body fluid analysis. Minimal damage to WBCs is attained using the lysis-free approach described in aspects of the disclosure.

US Patent:

20180128732, May 10, 2018

Filed:

Sep 14, 2017

Appl. No.:

15/704974

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 21/64
G01N 33/49
G01N 33/80
G01N 15/00
G01N 15/10

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.

US Patent:

20160018312, Jan 21, 2016

Filed:

Jul 24, 2015

Appl. No.:

14/808720

Inventors:

- Abbott Park IL, US
Marilou Coleman - Newark CA, US
Emily H. Lin - Cupertino CA, US
Michael R. Buhl - San Ramon CA, US
Giacomo Vacca - San Jose CA, US

International Classification:

G01N 15/14
G01N 21/64
G01N 33/49

Abstract:

Systems and methods for analyzing blood samples, and more specifically for performing a nucleated red blood cell (nRBC) analysis. The systems and methods screen a blood sample by means of fluorescence staining and a fluorescence triggering strategy, to identify nuclei-containing particles within the blood sample. As such, interference from unlysed red blood cells (RBCs) and fragments of lysed RBCs is substantially eliminated. The systems and methods also enable development of relatively milder reagent(s), suitable for assays of samples containing fragile white blood cells (WBCs). In one embodiment, the systems and methods include: (a) staining a blood sample with an exclusive cell membrane permeable fluorescent dye; (b) using a fluorescence trigger to screen the blood sample for nuclei-containing particles; and (c) using measurements of light scatter and fluorescence emission to distinguish nRBCs from WBCs.